PURPOSE OF REVIEW: Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT), despite improvements in our understanding of its pathophysiology as well as the generation of new monoclonal antibodies, immunomodulatory chemotherapy, cellular therapeutics and supportive care. Herein, we review therapies that have proven effective as well as newer agents that have recently improved GVHD response rates and survival following HCT. RECENT FINDINGS: Novel approaches to prevent or treat GVHD are often based on evidence from experimental models. Our understanding of the pathophysiology of GVHD may lead to the development of innovative strategies that target both soluble and cellular effectors. Among such agents are sirolimus, anti-tumor necrosis factor antibodies, anti-LFA-3-IgG fusion protein, extracorporeal photopheresis, mesenchymal stem cells and regulatory T cells. SUMMARY: Obstacles to the improvement of HCT include the tight linkage between GVHD toxicity and the beneficial graft-versus-leukemia (GVL) effect, as well as the impairment of immune reconstitution by immunomodulatory drugs leading to life-threatening infections. The design of newer phase I/II clinical trials are underway. Future therapies are likely to include modulation of cell types that play key roles in the GVH process, including regulatory T cells, dendritic cells, natural killer T cells and B cells.
PURPOSE OF REVIEW: Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT), despite improvements in our understanding of its pathophysiology as well as the generation of new monoclonal antibodies, immunomodulatory chemotherapy, cellular therapeutics and supportive care. Herein, we review therapies that have proven effective as well as newer agents that have recently improved GVHD response rates and survival following HCT. RECENT FINDINGS: Novel approaches to prevent or treat GVHD are often based on evidence from experimental models. Our understanding of the pathophysiology of GVHD may lead to the development of innovative strategies that target both soluble and cellular effectors. Among such agents are sirolimus, anti-tumornecrosis factor antibodies, anti-LFA-3-IgG fusion protein, extracorporeal photopheresis, mesenchymal stem cells and regulatory T cells. SUMMARY: Obstacles to the improvement of HCT include the tight linkage between GVHD toxicity and the beneficial graft-versus-leukemia (GVL) effect, as well as the impairment of immune reconstitution by immunomodulatory drugs leading to life-threatening infections. The design of newer phase I/II clinical trials are underway. Future therapies are likely to include modulation of cell types that play key roles in the GVH process, including regulatory T cells, dendritic cells, natural killer T cells and B cells.
Authors: E Calore; A Calò; G Tridello; S Cesaro; M Pillon; S Varotto; M V Gazzola; R Destro; P Marson; L Trentin; M Carli; C Messina Journal: Bone Marrow Transplant Date: 2008-06-23 Impact factor: 5.483
Authors: Vu H Nguyen; Sumana Shashidhar; Daisy S Chang; Lena Ho; Neeraja Kambham; Michael Bachmann; Janice M Brown; Robert S Negrin Journal: Blood Date: 2007-10-04 Impact factor: 22.113
Authors: Alana A Kennedy-Nasser; Catherine M Bollard; G Doug Myers; Kathryn S Leung; Stephen Gottschalk; Yiqun Zhang; Hao Liu; Helen E Heslop; Malcolm K Brenner; Robert A Krance Journal: Biol Blood Marrow Transplant Date: 2008-11 Impact factor: 5.742
Authors: John E Levine; Sophie Paczesny; Shin Mineishi; Thomas Braun; Sung W Choi; Raymond J Hutchinson; Dawn Jones; Yasser Khaled; Carrie L Kitko; Daniel Bickley; Oleg Krijanovski; Pavan Reddy; Gregory Yanik; James L M Ferrara Journal: Blood Date: 2007-11-27 Impact factor: 22.113
Authors: Erin Gatza; Daniel R Wahl; Anthony W Opipari; Thomas B Sundberg; Pavan Reddy; Chen Liu; Gary D Glick; James L M Ferrara Journal: Sci Transl Med Date: 2011-01-26 Impact factor: 17.956
Authors: Leslie S Kean; Sharon Sen; Olusegun Onabajo; Karnail Singh; Jennifer Robertson; Linda Stempora; Aylin C Bonifacino; Mark E Metzger; Daniel E L Promislow; Joseph J Mattapallil; Robert E Donahue Journal: Blood Date: 2011-10-11 Impact factor: 22.113
Authors: Najib El Haddad; Dean Heathcote; Robert Moore; Sunmi Yang; Jamil Azzi; Bechara Mfarrej; Mark Atkinson; Mohamed H Sayegh; Jeng-Shin Lee; Philip G Ashton-Rickardt; Reza Abdi Journal: Blood Date: 2010-11-12 Impact factor: 22.113
Authors: Nancy Y Villa; Clive H Wasserfall; Amy M Meacham; Elizabeth Wise; Winnie Chan; John R Wingard; Grant McFadden; Christopher R Cogle Journal: Blood Date: 2015-04-22 Impact factor: 22.113
Authors: Abdellatif Bouazzaoui; Elisabeth Huber; Alexander Dan; Faisal A Al-Allaf; Jochen Pfirstinger; Günter Sprotte; Josef Köstler; Andreas Hiergeist; Andre Gessner; Wolfgang Herr; Ernst Holler Journal: Blood Date: 2016-12-23 Impact factor: 22.113